This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ؍ 60
✦ LIBER ✦
Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy
✍ Scribed by Chih-Lin Lin; Li-Ying Liao; Chaur-Shine Wang; Pei-Jer Chen; Ming-Yang Lai; Ding-Shinn Chen; Jia-Horng Kao
- Book ID
- 111237217
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 124 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0106-9543
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Efficacy of lamivudine in patients with
✍
Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar
📂
Article
📅
1999
🏛
John Wiley and Sons
🌐
English
⚖ 152 KB
👁 1 views
Comparison of sequence changes of precor
✍
Chien-Hung Chen; Chuan-Mo Lee; Sheng-Nan Lu; Chi-Sin Changchien; Jyh-Chwan Wang;
📂
Article
📅
2006
🏛
Elsevier Science
🌐
English
⚖ 124 KB
Mutations in the Basal Core Promoter and
✍
C. Mayerat; A. Mantegani; F. Spertini; P. C. Frei
📂
Article
📅
1999
🏛
Springer
🌐
English
⚖ 158 KB
Evolution of Hepatitis B Virus Polymeras
✍
Anna Suk-Fong Lok; Munira Hussain; Carmela Cursano; Marzia Margotti; Annagiulia
📂
Article
📅
2000
🏛
John Wiley and Sons
🌐
English
⚖ 236 KB
Mutations of polymerase, precore and cor
✍
Fumitaka Suzuki; Yoshiyuki Suzuki; Akihito Tsubota; Norio Akuta; Takashi Someya;
📂
Article
📅
2002
🏛
Elsevier Science
🌐
English
⚖ 103 KB
Precore/core promoter mutations and geno
✍
Chun-Jen Liu; Jia-Horng Kao; Ming-Yang Lai; Pei-Jer Chen; Ding-Shinn Chen
📂
Article
📅
2004
🏛
John Wiley and Sons
🌐
English
⚖ 77 KB
👁 2 views
## Abstract The association of precore stop codon mutation (A1896), dinucleotide mutation (T1762/A1764) in the basic core promoter of hepatitis B virus (HBV) genome, and genotype of HBV with fulminant or subfulminant hepatitis remains controversial. We studied HBV genotypes as well as mutations in